Maternal antiretroviral prophylaxis and breastfeeding

Antiviral Therapy

Volumn 17, Issue 8, 2012, Pages 1503-1506

  Marzolini, Catia ^a   Gray, Glenda E ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

BREAST FEEDING; BREAST MILK; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; MATERNAL SERUM; NONHUMAN; NOTE; PREGNANCY; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; BREAST FEEDING; FEMALE; HIV INFECTIONS; HUMANS; MALE; PREGNANCY; PREMEDICATION;

EID: 84871872183     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2314     Document Type: Note

References (36)

1. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283:1167-1174. (Pubitemid 30126605)
2. Breastfeeding and HIV International Transmission Study Group. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004; 189:2154-2166.
3. Scarlatti G. Mother-to-child transmission of HIV-1: advances and controversies of the twentieth centuries. AIDS Rev 2004; 6:67-78. (Pubitemid 39149445)
4. + T cells spontaneously producing human immunodeficiency virus type I in breast milk from women with or without antiretroviral drugs. Retrovirology 2011; 8:34.
5. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183:206-212. (Pubitemid 32066020)
6. Pillay K, Coutsoudis A, York D, et al. Cell-free virus in breast milk of HIV-1-seropositive women. J Acquir Immune Defic Syndr 2000; 24:330-336.
7. Richardson BA, John-Stewart GC, Hughes JP, et al. Breastmilk infectivity in human immunodeficiency virus type1-infected mothers. J Infect Dis 2003; 187:736-740. (Pubitemid 36286933)
8. Rousseau CM, Nduati RW, Richardson BA, et al. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis 2004; 190:1880-1888. (Pubitemid 39487835)
9. Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999; 180:93-98. (Pubitemid 29293922)
10. Shapiro RL, Ndung'u T, Lockman S, et al. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis 2005; 192:713-719. (Pubitemid 41193068)
11. Van de Perre P. Mother-to-child transmission of HIV-1: the 'all mucosal' hypothesis as a predominant mechanism of transmission. AIDS 1999; 13:1133-1138. (Pubitemid 29361405)
12. Koulinska IN, Villamor E, Chaplin B, et al. Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J 'Acquir Immune Defic Syndr 2006; 41:93-99.
13. John-Stewart G, Mbori-Ngacha D, Ekpini R, et al. Breastfeeding and transmission of HIV-1. J Acquir Immune Defic Syndr 2004; 35:196-202.
14. WHO/UNAIDS/UNICEF. Progress report 2011: Global HIV/AIDS response. Epidemic update and health sector progress towards universal access (Updated 30 November 2011. Accessed 14 May 2012.) Available from www.who.int/hiv/pub/ progress-report2011/en/index.html
15. Manigart O, Crepin M, Leroy V, et al. Effect of perinatal zidovudine prophylaxis on the evolution of cell-free HIV-1 RNA in breast milk and on postnatal transmission. J Infect Dis 2004; 190:1422-1428. (Pubitemid 39332181)
16. Lehman DA, Chung MH, John-Stewart GC, et al. HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS 2008; 22:1475-1485.
17. Becquart P, Petitjean G, Tabaa YA, et al. Detection of a large T-cell reservoir able to replicate HIV-1 actively in breast milk. AIDS 2006; 20:1453-1455. (Pubitemid 43948254)
18. Palombi L, Pirillo MF, Andreotti M, et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther 2012; in press.
19. Rezk NL, White N, Bridges A, et al. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit 2008; 30:611-619.
20. Corbett A, Martinson F, Rezk N, et al. Lopinavir/ritonavir concentrations in breast milk and breast-feeding infants. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, Canada. Abstract 947.
21. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breastfeeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192:720-727. (Pubitemid 41193069)
22. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53:1170-1176.
23. Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr 2008; 48:450-454.
24. Colebunders R, Hodossy B, Burger D, et al. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS 2005; 19:1912-1915. (Pubitemid 41546612)
25. Corbett A, Kashuba A, Rezk N, et al. Antiretroviral drug concentrations in breast milk and breastfeeding infants. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 648.
26. Weidle PJ, Zeh C, Martin A, et al. Nelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breastfeeding infants whose mothers are taking nelfinavir. Antimicrob Agents Chemother 2011; 55:5168-5171.
27. Spencer L, Neely M, Mordwinkin N, et al. Intensive pharmacokinetics of zidovudine, lamivudine, and atazanavir and HIV-1 viral load in breast milk and plasma in HIV+ women receiving HAART. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, Canada. Abstract 942.
28. Ito S, Lee A. Drug excretion into breast milk - overview. Adv Drug Deliv Rev 2003; 55:617-627. (Pubitemid 36428675)
29. Jonker JW, Merino G, Musters S, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 2005; 11:127-129. (Pubitemid 40321346)
30. Vlaming MLH, Lagas JS, Schinkel AH. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev 2009; 61:14-25.
31. Weiss J, Rose J, Storch CH, et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007; 59:238-245. (Pubitemid 47072063)
32. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single arm trial of triple antiretroviral prophylaxis for prevention of mother-tochild transmission: a secondary analysis. PLoS Med 2011; 8:e1000430.
33. La Porte CJL, Back DJ, Blaschke T, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Reviews in Antiviral Therapy 2006; 3:4-14.
34. Mofenson LM. Antiretroviral drugs to prevent breastfeeding HIV transmission. Antivir Ther 2010; 15:537-553.
35. Slyker JA, Chung MH, Lehman DA, et al. Incidence and correlates of HIV-1 RNA detection in the breast milk of women receiving HAART for the prevention of HIV-1 transmission. PLoS ONE 2012; 7:e29777.
36. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204:506-514.